Skip to main content
Premium Trial:

Request an Annual Quote

ABI Q1 Revenues Down, While Net Income Nearly Doubles

NEW YORK, Oct. 22 (GenomeWeb News) - Applied Biosystems this morning reported net revenues of $382.7 million for the first fiscal quarter ending Sept. 30, down $13.2 million compared to the same quarter of 2002.


Despite this drop in revenues, the company reported an increase in net income year-over-year: Net income rose  to $33.4 million for the quarter, compared to $17.8 million for the year-ago period. This rise in net income reflects the fact that the company recorded a loss of $16.4 million from discontinued operations the same period last year.


Broken down by sector, the company's DNA sequencing revenues dropped to $124.8 million, compared to $149.3 million in the first fiscal quarter of 2003; SDS and other applied genomics revenues increased to $94.3 million, from $83.5 million in the same period last year; mass spectrometry revenues were nearly flat at $82.4 million, compared to $84.2 million in the year-ago quarter; core DNA synthesis and PCR revenues increased slightly to $51.2 million, from $49.0 million in the same period last year; and other product lines were flat at $30.0 million, compared to $29.9 million in the same period last year.


The company recorded research and development expenses of $59.6 million, compared to $61 million for the same quarter in 2002. 

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.